patients with type 2 diabetes mellitus inadequately controlled despite a treatment with sulfonylurea (su) alone or metformin alone or a free combination of su and metformin prior to the study entry.

signed informed consent, obtained prior any study procedure

age < legal age of adulthood

hba1c < 7% or ≥ 11%

bmi > 35 kg/m2

treatment with a stable dose of maximally tolerated su alone or metformin alone or the free combination of su and metformin for less than 12 weeks prior to the screening visit.

patients who received any anti-diabetic drug other than su or metformin within 12 weeks prior to the screening visit.

diabetes other than type 2 diabetes (e.g. type 1 diabetes, diabetes secondary to pancreatic disorders, drug or chemical agent intake…)

the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.